ResultsIQ

ResultsIQ › Latest results › Orchid Pharma Limited

Orchid Pharma Limited Q1 FY26 earnings call summary

NSE: ORCHPHARMA · BSE: 524372

Earnings call of 12 Aug 2025, summarised by AI from the filing.

Orchid Pharma Q1 FY26 sales fell 29% to ₹173 cr amid antibiotics slowdown; acquired global rights to Enmetazobactam from Allecra.

Key takeaways

  1. Q1 sales ₹173 cr (Q1 FY25: ₹244 cr), a steep decline of around 29% due to antibiotics market slowdown.
  2. Guidance No revival in antibiotics market seen in the near future, at least not in the current year.
  3. Acquisition Orchid acquired global rights to Enmetazobactam and Exblifep from Allecra, funded from internal accruals.
  4. Risk Persistent volume and price pressure in antibiotics could weigh on near-term revenues.

Original filing on BSE

Orchid Pharma Limited Q1 FY27 results

As filed: Revenue ₹304 cr (+76% year on year), EBITDA ₹14.0 cr (−7% year on year), PAT ₹3.2 cr (−79% year on year), EBITDA margin 4.6% (−407 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹368 cr (+55% year on year), EBITDA ₹30.2 cr (+8% year on year), PAT ₹25.8 cr (+17% year on year), EBITDA margin 8.2% (−363 bps). Score 66 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 363 bps year on year. Other income 31% of PBT. Tax rate 0%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +38.9% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹207 cr (−4% year on year), EBITDA ₹1.6 cr (−94% year on year), PAT −₹12.6 cr (−123% year on year), EBITDA margin 0.8% (−1,000 bps). Score 20 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 1000 bps year on year. Share price after the results: −25.8% in 30 days (Nifty 500: −10.1%).
  • Q2 FY26: Revenue ₹194 cr (−13% year on year), EBITDA −₹1.0 cr (−103% year on year), PAT −₹6.0 cr (−122% year on year), EBITDA margin -0.5% (−1,000 bps). Score 20 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 1000 bps year on year. Profit fell 140% from last quarter. Share price after the results: +0.6% in 30 days (Nifty 500: −0.2%).
  • Q1 FY26: Revenue ₹173 cr (−29% year on year), EBITDA ₹15.0 cr (−53% year on year), PAT ₹15.0 cr (−48% year on year), EBITDA margin 8.7% (−444 bps). Score 7 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 444 bps year on year. Other income 79% of PBT. Tax rate 0%. Revenue fell 27% from last quarter. Share price after the results: −7.0% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹237 cr (+9% year on year), EBITDA ₹28.0 cr (0% year on year), PAT ₹22.0 cr (−33% year on year), EBITDA margin 11.8% (−109 bps). Score 34 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 109 bps year on year. Tax rate 0%. Share price after the results: −5.1% in 30 days (Nifty 500: +1.7%).
  • Q3 FY25: Revenue ₹217 cr (−2% year on year), EBITDA ₹27.0 cr (−23% year on year), PAT ₹21.0 cr (−28% year on year), EBITDA margin 12.4% (−339 bps). Score 13 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 339 bps year on year. Other income 36% of PBT. Tax rate 0%. Profit fell 22% from last quarter.
  • Q2 FY25: Revenue ₹223 cr (+12% year on year), EBITDA ₹30.0 cr (+25% year on year), PAT ₹27.0 cr (+35% year on year), EBITDA margin 13.5% (+139 bps). Score 55 of 100, In line with trend. EBITDA margin rose 139 bps year on year. Other income 31% of PBT. Tax rate 0%. Not enough history for a trend yet: scored on growth alone. Revenue fell 9% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Orchid Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.